Abstract 4023
Background
Sentinel lymph node dissection (SLND) after neoadjuvant chemotherapy (NAC) is of questionable accuracy. In this study we evaluated the feasibility and accuracy of SLND in breast cancer patients with clinically positive axillary nodes.
Methods
We conducted a prospective cross-sectional study on breast cancer patients diagnosed at Milad Hospital of Tehran, Iran from June 2014 to February 2015. Biopsy-proven node positive patients who converted to clinically node-negative following NAC and had a successful SLND (more than three identified SLNs) were included in the study. We used a 2 × 2 contingency table to analyze the feasibility of SLNB (sensitivity, specificity, false negative ratio, and accuracy). STATA statistical software (version 13.0, StataCorp LP, Texas, USA) was used for statistical analysis.
Results
Among 52 patients who entered the study, 47 had a successful SLND (more than three identified SLNs) in whom we achieved a sensitivity of 100% (16/16), false-negative rate of 0% (0/21), a negative predictive value of 100% (16/16), and an overall accuracy of 89.4%.
Conclusions
SLND seems to be feasible and accurate in clinically lymph node positive breast cancer patients who achieve a clinically negative node status following neoadjuvant chemotherapy.
Clinical trial identification
Legal entity responsible for the study
Iran University of Medical Sciences.
Funding
Milad General Hospital - Iran National Social Security Organization.
Editorial Acknowledgement
Disclosure
All authors have declared no conflicts of interest.